CO5190704A1 - METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS - Google Patents

METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS

Info

Publication number
CO5190704A1
CO5190704A1 CO00053306A CO00053306A CO5190704A1 CO 5190704 A1 CO5190704 A1 CO 5190704A1 CO 00053306 A CO00053306 A CO 00053306A CO 00053306 A CO00053306 A CO 00053306A CO 5190704 A1 CO5190704 A1 CO 5190704A1
Authority
CO
Colombia
Prior art keywords
cycloalkyl
alkyl
phenyl
alkynyl
alkenyl
Prior art date
Application number
CO00053306A
Other languages
Spanish (es)
Inventor
Stephen Douglas Barrett
Alexander James Bridges
Haile Tecle
Alistair Dixon
Kevin Lee
Robert Denham Pinnock
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5190704A1 publication Critical patent/CO5190704A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Un método para tratar el dolor crónico, dicho método caracterizado porque comprende administrar a un sujeto que necesita el tratamiento, una composición que comprende un inhibidor de MEK seleccionado de un compuesto de la siguiente fórmula (I) :<EMI FILE="00053306_1" ID="1" IMF=JPEG >en dondeW es OR1, NR2OR1, NRARB, NR2NRARB, O (CH2) 2-4 NRARB, o NR2(CH2) 2-4 NRARB;R1 es H, alquilo de C1-8, alquenilo de C3-8, alquinilo de C3-8, cicloalquilo de C3-8, fenilo, (fenil)alquilo de C1-4, (fenil)alquenilo de C3-4, (fenil) alquinilo de C3-4, (cicloalquilo de C3-8)alquilo de C1-4, ((cicloalquilo de C3-8) alquenilo de C3-4, (cicloalquilo de C3-8) alquinilo de C3-4, radical heterocíclico de C3-8, (radical heterocíclico de C3-8)alquilo de C1-4, (radical heterocíclico de C3-8)alquenilo de C3-4, (radical heterocíclico de C3-8)alquinilo de C3-4 o (CH2)2-4 NRCRD;R2 es H, alquilo de C1-4, fenilo, cicloalquilo de C3-6, radical heterocíclico de C3-6, o (cicloalquilo de C3-6)metilo;RA es H, alquilo de C1-6, alquenilo de C3-8, alquinilo de C3-8, cicloalquilo de C3-8, fenilo, (cicloalquilo de C3-8) alquilo de C1-4, (cicloalquilo de C3-8) alquenilo de C3-4, (cicloalquilo de C3-8)alquinilo de C3-4, radical heterocíclico de C3-8, (radical heterocíclico de C3-8)alquilo de C1-4, (aminosulfonill)fenilo, [(aminosulfonil)fenil]alquilo de C1-4, (aminosulfonil)alquilo de C1-6, (aminosulfonil)cicloalquilo de C3-6, [(aminosulfonil)cicloalquilo de C3-6]alquilo de C1-4, o (CH2)2-4 NRCRD;RB es H, alquilo de C1-8, alquenilo de C3-8, alquinilo de C3-8, cicloalquilo de C3-8, o fenilo;Q es una de las siguientes fórmulas (i) -(iii):<EMI FILE="00053306_2" ID="2" IMF=JPEG >R3 es H o F;R4 es halo, NO2, SO2NRO(CH2)2-4NRERF, SO2NRERF o (CO)T;T es alquilo de C1-8, cicloalquilo de C3-8, (NRERF)alquilo de C1-4, ORF, -NRO(CH2)2-4NRERF, o NRERF; ...A method for treating chronic pain, said method characterized in that it comprises administering to a subject in need of treatment, a composition comprising an MEK inhibitor selected from a compound of the following formula (I): <EMI FILE = "00053306_1" ID = "1" MFI = JPEG> where W is OR1, NR2OR1, NRARB, NR2NRARB, O (CH2) 2-4 NRARB, or NR2 (CH2) 2-4 NRARB; R1 is H, C1-8 alkyl, alkenyl of C3-8, C3-8 alkynyl, C3-8 cycloalkyl, phenyl, C4-4 (phenyl) alkyl, C3-4 (phenyl) alkenyl, (C3-4 phenyl) alkynyl, (C3- cycloalkyl) 8) C1-4 alkyl, ((C3-8 cycloalkyl) C3-4 alkenyl, (C3-8 cycloalkyl) C3-4 alkynyl, C3-8 heterocyclic radical, (C3-8 heterocyclic radical) C1-4 alkyl, (C3-8 heterocyclic radical) C3-4 alkenyl, (C3-8 heterocyclic radical) C3-4 alkynyl or (CH2) 2-4 NRCRD; R2 is H, C1- alkyl 4, phenyl, C3-6 cycloalkyl, C3-6 heterocyclic radical, or (C3-6 cycloalkyl) methyl; RA is H, alkyl C1-6, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, phenyl, (C3-8 cycloalkyl) C1-4 alkyl, (C3-8 cycloalkyl) C3- alkenyl 4, (C3-8 cycloalkyl) C3-4 alkynyl, C3-8 heterocyclic radical, (C3-8 heterocyclic radical) C1-4 alkyl, (aminosulfonill) phenyl, [(aminosulfonyl) phenyl] C1 alkyl -4, (aminosulfonyl) C1-6 alkyl, (aminosulfonyl) C3-6 cycloalkyl, [(aminosulfonyl) C3-6 cycloalkyl] C1-4 alkyl, or (CH2) 2-4 NRCRD; RB is H, C1-8 alkyl, C3-8 alkenyl, C3-8 alkynyl, C3-8 cycloalkyl, or phenyl; Q is one of the following formulas (i) - (iii): <EMI FILE = "00053306_2" ID = "2" IMF = JPEG> R3 is H or F; R4 is halo, NO2, SO2NRO (CH2) 2-4NRERF, SO2NRERF or (CO) T; T is C1-8 alkyl, C3-8 cycloalkyl, ( NRERF) C1-4 alkyl, ORF, -NRO (CH2) 2-4NRERF, or NRERF; ...

CO00053306A 1999-07-16 2000-07-14 METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS CO5190704A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14441899P 1999-07-16 1999-07-16

Publications (1)

Publication Number Publication Date
CO5190704A1 true CO5190704A1 (en) 2002-08-29

Family

ID=22508500

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00053306A CO5190704A1 (en) 1999-07-16 2000-07-14 METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS

Country Status (13)

Country Link
EP (1) EP1202731A2 (en)
JP (1) JP2003504398A (en)
KR (1) KR20020015376A (en)
CN (1) CN1358094A (en)
AU (1) AU6068600A (en)
CA (1) CA2377092A1 (en)
CO (1) CO5190704A1 (en)
HU (1) HUP0202319A3 (en)
IL (1) IL147150A0 (en)
PE (1) PE20010546A1 (en)
PL (1) PL352835A1 (en)
WO (1) WO2001005390A2 (en)
ZA (1) ZA200109906B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035971A1 (en) 2001-05-16 2004-07-28 Cephalon Inc METHODS FOR THE TREATMENT AND PREVENTION OF PAIN
WO2002102232A2 (en) * 2001-06-14 2002-12-27 The Regents Of The University Of California A novel signaling pathway for the production of inflammatory pain and neuropathy
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
UA76837C2 (en) * 2002-03-13 2006-09-15 Еррей Байофарма Інк. N3 alkylated derivatives of benzimidazole as mek inhibitors
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0213383D0 (en) * 2002-06-11 2002-07-24 Cambridge Biotechnology Ltd Therapeutic conditions
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CA2532067C (en) * 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
JP5042626B2 (en) 2003-09-22 2012-10-03 エス＊バイオ プライベート リミティッド Benzimidazole derivatives: production and pharmaceutical applications
AU2004293019B2 (en) 2003-11-19 2010-10-28 Array Biopharma Inc. Bicyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
KR101223914B1 (en) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Akt protein kinase inhibitors
TWI441637B (en) 2005-05-18 2014-06-21 Array Biopharma Inc Heterocyclic inhibitors of mek and methods of use thereof
AU2006262259B2 (en) 2005-06-23 2013-03-14 Array Biopharma Inc. Process for preparing benzimidazole compounds
EA019983B1 (en) 2005-10-07 2014-07-30 Экселиксис, Инк. Mek inhibitors and methods of using same
MY147628A (en) 2006-07-06 2012-12-31 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
DE602007011628D1 (en) 2006-07-06 2011-02-10 Array Biopharma Inc DIHYDROFUROPYRIMIDINES AS ACT PROTEIN KINASE INHIBITORS
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2671982C (en) 2006-12-14 2016-01-26 Exelixis, Inc. Methods of using mek inhibitors
CA2692506C (en) 2007-07-05 2015-11-24 Array Biopharma Inc. Pyrimidyl cyclopentanes as akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (en) 2007-07-05 2015-03-11 阵列生物制药公司 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
CA2706571C (en) 2007-12-19 2012-11-27 Genentech, Inc. 5-anilinoimidazopyridines and methods of use
AU2008343062B2 (en) 2007-12-19 2013-03-07 Genentech, Inc. 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
KR20100099185A (en) 2007-12-21 2010-09-10 제넨테크, 인크. Azaindolizines and methods of use
EP2240455B1 (en) 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
CA2711699A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
JP5615274B2 (en) 2008-07-01 2014-10-29 ジェネンテック， インコーポレイテッド Isoindolone derivatives as MEK kinase inhibitors and methods of use thereof
ES2399384T3 (en) 2008-11-10 2013-04-01 Bayer Schering Pharma Ag Sulfonamido substituted phenoxybenzamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
CA2777430A1 (en) 2009-10-21 2011-04-28 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
CN103841976A (en) 2011-04-01 2014-06-04 基因泰克公司 Combinations of AKT AND MEK inhibitor compounds, and methods of use
SG194048A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
ES2396764B1 (en) 2011-11-02 2013-12-19 Universidad Autónoma de Madrid P38 INHIBITING DRUGS AND APPLICATIONS.
TWI519515B (en) 2011-12-21 2016-02-01 諾維拉治療公司 Hepatitis b antiviral agents
CN103204822B (en) 2012-01-17 2014-12-03 上海科州药物研发有限公司 Benzoxazole compounds as protein kinase inhibitors, and preparation method and application thereof
EA027280B1 (en) 2012-08-28 2017-07-31 Янссен Сайенсиз Айрлэнд Юси Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. Novel process for making compounds for use in the treatment of cancer
LT3702351T (en) * 2012-10-19 2024-01-10 Array Biopharma, Inc. Formulation comprising a mek inhibitor
CA2899706C (en) 2013-02-28 2021-10-19 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US9895349B2 (en) 2013-04-03 2018-02-20 Janssen Sciences Ireland Us N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
NO3024819T3 (en) 2013-07-25 2018-07-21
CA2923712C (en) 2013-10-23 2021-11-02 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN104774188B (en) * 2014-01-15 2019-10-11 江苏恒瑞医药股份有限公司 Benzo-heterocycle or benzo hetero-aromatic ring analog derivative, preparation method and its application in medicine
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (en) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Combined therapy for treating hepatitis b infections
CN110483484A (en) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
CN107847762A (en) 2015-03-19 2018-03-27 诺维拉治疗公司 Azacyclooctane and azacyclo- nonane derivatives and the method for treating hepatitis B infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
EP3442524A2 (en) 2016-04-15 2019-02-20 Novira Therapeutics Inc. Combinations and methods comprising a capsid assembly inhibitor
AR108257A1 (en) 2016-05-02 2018-08-01 Mei Pharma Inc POLYMORPHIC FORMS OF 3- [2-BUTIL-1- (2-DIETILAMINO-ETIL) -1H-BENCIMIDAZOL-5-IL] -N-HYDROXY-ACRYLAMIDE AND USES OF THE SAME
US10973801B2 (en) 2018-03-14 2021-04-13 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
US11096931B2 (en) 2019-02-22 2021-08-24 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US11491148B2 (en) 2019-05-06 2022-11-08 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
CN110981819B (en) * 2019-12-24 2022-07-01 广西师范大学 Quinoxaline signal channel inhibitor and preparation method and application thereof
CN114788867A (en) * 2022-04-24 2022-07-26 天津医科大学总医院 Application of Map2k1 as therapeutic target of postchemotherapy neuralgia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
ATE302193T1 (en) * 1999-01-13 2005-09-15 Warner Lambert Co BENZOHETEROCYCLES AND THEIR USE AS MEK INHIBITORS

Also Published As

Publication number Publication date
CA2377092A1 (en) 2001-01-25
WO2001005390A3 (en) 2001-05-17
EP1202731A2 (en) 2002-05-08
AU6068600A (en) 2001-02-05
HUP0202319A3 (en) 2004-12-28
CN1358094A (en) 2002-07-10
KR20020015376A (en) 2002-02-27
PE20010546A1 (en) 2001-06-04
PL352835A1 (en) 2003-09-08
WO2001005390A2 (en) 2001-01-25
IL147150A0 (en) 2002-08-14
JP2003504398A (en) 2003-02-04
HUP0202319A2 (en) 2002-10-28
ZA200109906B (en) 2003-05-28

Similar Documents

Publication Publication Date Title
CO5190704A1 (en) METHOD TO TREAT CHRONIC PAIN USING MEK INHIBITORS
FI945426A0 (en) GABA and L-glutamic acid analogues for anti-seizure therapy
ATE395056T1 (en) USE OF R-(+)-2-(3-DIISOPROPYLAMINO-1-PHENYLPROPYL)-4-HYDROXY-METHYL-PHENYLISOBUTYRIC ACID ESTER HYDROGEN FUMARATE FOR THE TREATMENT OF URINARY INCONTINENCE AND OTHER SPASMOGENIC CONDITIONS
ATE292462T1 (en) TREATMENT OF ASTHMA USING MEK INHIBITORS
DE69512797T2 (en) PROSTAGLANDIN SYNTHASE HEMMER
FI974180A (en) Spirocyclic and bicyclic diazinyl and carbazinyloxazolidinones
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
DK0775129T3 (en) 3-Benzoylbenzofuran derivatives as thyroid hormone antagonists
DK0699439T3 (en) Treatment of diseases caused by sebaceous glands with acyl-CoA-cholesterolacyltransferase inhibitors
CO5180605A1 (en) INDOL COMPOUNDS
DE69229442T2 (en) SUBSTITUTED DIBENZOOXAZEPIN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE
FI863488A0 (en) FOERENINGAR.
AR031032A1 (en) USE OF TOLTERODINE IN THE TREATMENT OF ASTHMA
DK0607777T3 (en) Use of leflunomide to inhibit interleukin 8
KR970706811A (en) Preventive and remedy for allergic diseases of type I
FI833453A0 (en) THERAPEUTIC MEDEL
DE602006018710D1 (en) CYTOKIN MODULATORS USING CYCLIC GLYCERIDES OF ESSENTIAL MULTIPLE UNSATURATED FATTY ACIDS
AR002264A1 (en) 6- [TRIAZOLIL [3 (TRIFLUORMETIL) FENIL] METHYL] -2-QUINOLINONES AND QUINOLINTIONS, A PROCEDURE FOR THEIR PREPARATION, A COMPOSITION THAT INCLUDES THEM, A PROCEDURE FOR THEIR PREPARATION, THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT INTERMEDIARY.
AR036891A1 (en) ROSUVASTATINA IN PREDEMENTIAL STATES
DK0446921T3 (en) Optically active alkylenedioxybenzene derivatives and their use in therapy
ATE415980T1 (en) CLEANING AND DISINFECTING AGENTS FOR MEDICAL INSTRUMENTS WITH IMPROVED EFFECTIVENESS AGAINST HEPATITIS B VIRUSES
RU2004103625A (en) NEW MANDALIC ACID DERIVATIVES AND THEIR APPLICATION AS THROMBINE INHIBITORS
DE60108775T8 (en) METHOD FOR THE TREATMENT OF STROKE
RU2335492C2 (en) New 5,6-dihydropyridine-2-on compounds applicable as thrombin inhibitors
ATE279182T1 (en) USE OF SPECIAL COMPOUNDS FOR PROPHYLAXIS AND THERAPY OF HEPATITIS C

Legal Events

Date Code Title Description
FC Application refused